Skip to main content

Exosome Diagnostics, German University Receive €1M Grant to Develop Cancer Dx Tests


Exosome Diagnostics and the department of dermatology at the Ludwig Maximilian University in Munich have been awarded a €1 million ($1.3 million) grant from the German government to develop diagnostic cancer tests based on RNA from plasma-derived exosomes.

Under the grant, from the German Federal Ministry for Education and Research, the researchers plan to develop diagnostic technology to detect tumor-specific mutations in the blood of patients with malignant cancer in order to monitor disease recurrence, aid therapy selection, and possibly improve early tumor detection. The partners plan to couple exosome-based technology with next-generation sequencing and qPCR instrument platforms.

Exosome Diagnostics plans to offer clinical diagnostic tests developed under the project commercially at its laboratories in St. Paul, Minn., and Munich.

Microvesicles, which include exosomes, contain large quantities of tumor-derived mRNA found in biofluids outside of tumor cells. They provide a stable source of RNA in blood, urine, and spinal fluid.

The company has been developing a multiplexed sequencing method for mRNA from blood and urine exosome preparations, which allows for the sensitive detection of rare gene mutations.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.